Cognoptix

Cognoptix, based in Concord, MA, is at the forefront of early Alzheimer's disease detection with its innovative Sapphire II system, a non-invasive eye scanning device that identifies beta-amyloid proteins in the lens of the eye. Co-founded by Dr. Lee Goldstein and Dr. Leo Chylack from Brigham and Women's Hospital, the company aims to provide a highly accurate and cost-effective solution for diagnosing Alzheimer's before more invasive interventions are required.

The company has garnered attention for its commitment to pioneering non-invasive diagnostic methods, addressing the significant unmet need for early detection tools in Alzheimer's care. With ongoing development of its laser eye scanning technology, Cognoptix is actively forming strategic alliances to enhance its diagnostic platform and prepare for clinical use.

Generated from the website